ORKA (Oruka Therapeutics) EV-to-Revenue : (As of May. 29, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Oruka Therapeutics's enterprise value is $83.10 Mil. Oruka Therapeutics does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate Oruka Therapeutics's EV-to-Revenue at this moment.

The historical rank and industry rank for Oruka Therapeutics's EV-to-Revenue or its related term are showing as below:

ORKA's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.47
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-29), Oruka Therapeutics's stock price is $11.47. Oruka Therapeutics does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate Oruka Therapeutics's PS Ratio at this moment.

Oruka Therapeutics EV-to-Revenue Historical Data

The historical data trend for Oruka Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics EV-to-Revenue Chart

Oruka Therapeutics Annual Data

Trend

Dec24

EV-to-Revenue

Oruka Therapeutics Semi-Annual Data
	Dec24
EV-to-Revenue	-

Competitive Comparison of Oruka Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Oruka Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Oruka Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Oruka Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	83.103	/
	=

Oruka Therapeutics (NAS:ORKA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Oruka Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	11.47	/
	=

Oruka Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.